Chung RT, Bisceglie A, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Hamzeh FM. Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis c. Poster presented at the 2010 Digestive Disease Week; May 1, 2010. New Orleans, LA. [abstract] Gastroenterology. 2010 May; 138(5_suppl_1):S-841.
Kunzli N, Jerrett M, Garcia-Esteban R, Basagana X, Beckermann B, Gilliland F, Medina M, Peters J, Hodis HN, Mack WJ. Ambient air pollution and the progression of atherosclerosis in adults. PLoS One. 2010 Feb 8;5(2):e9096. doi: 10.1371/journal.pone.0009096
Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome foundation report. Gastroenterology. 2009 Dec 1;137(6):1944-53.
Gallego R, Codony-Servat J, Garcia-Albeniz X, Carcereny E, Longaron R, Oliveras A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr Relat Cancer. 2009 Mar;16(1):311-7. doi: 10.1677/ERC-08-0250
Johnson FR, Ozdemir F, Mansfield CA, Hass S, Miller DP, Siegel CA, Sands BE. Crohn's disease patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007 Sep;133(3):769-79.
Watson ME, Lacey LA, McSorley DJ, Kong NS, Northcutt AR, Mangel AW. Patient satisfaction with alosetron for the treatment of irritable bowel syndrome (IBS). Poster presented at the Digestive Disease Week and the 101st Annual Meeting of the American Gastroenterological Association; May 2000. [abstract] Gastroenterology. 2000 Apr; 118((4) Part 1):A219.
Northcutt AR, Camilleri M, Mayer EA, Dossman DA, Dukes GE, Ehsanullah RSB, McSorley DJ. Alosetron, a 5-HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology. 1998;114:A812.
Vakil N, McSorley DJ. The incremental cost and utility of cultures for helicobacter pylori. Gastroenterology. 1997;112(4):A319.
Perschy TB, McSorley DJ. Ranitidine bismuth citrate in combination with clarithromycin is effective against h. pylori strains with susceptible or intermediate clarithromycin sensitivity. Gastroenterology. 1997;112(4):A257.
Peterson WL, Sontag SJ, Ciociola AA, Sykes DL, McSorley DJ, Webb DD, the H. pylori Ulcer Group. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of helicobacter pylori and prevention of duodenal ulcer relapse. Poster presented at the Digestive Disease Week and the 95th Annual Meeting of the American Gastroenterological Association; May 1995. [abstract] Gastroenterology. 1995 Apr; 108(4 (Suppl 1)):A190. doi: 10.1016/0016-5085(95)23422-5
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of chronic oral dosing of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory activity. Gastroenterology. 1992;102(4):A50.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of ascending oral doses of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory properties. Gastroenterology. 1992;102(4):A51.